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Abstract
Background: Crohn’s Disease (CD) has a heterogeneous presentation, and is typically classified according to extent and
location of disease. The genetic susceptibility to CD is well known and genome-wide association scans (GWAS) and meta-
analysis thereof have identified over 30 susceptibility loci. Except for the association between ileal CD and NOD2 mutations,
efforts in trying to link CD genetics to clinical subphenotypes have not been very successful. We hypothesized that the large
number of confirmed genetic variants enables (better) classification of CD patients.
Methodology/Principal Findings: To look for genetic-based subgroups, genotyping results of 46 SNPs identified from CD
GWAS were analyzed by Latent Class Analysis (LCA) in CD patients and in healthy controls. Six genetic-based subgroups
were identified in CD patients, which were significantly different from the five subgroups found in healthy controls. The
identified CD-specific clusters are therefore likely to contribute to disease behavior. We then looked at whether we could
relate the genetic-based subgroups to the currently used clinical parameters. Although modest differences in prevalence of
disease location and behavior could be observed among the CD clusters, Random Forest analysis showed that patients
could not be allocated to one of the 6 genetic-based subgroups based on the typically used clinical parameters alone. This
points to a poor relationship between the genetic-based subgroups and the used clinical subphenotypes.
Conclusions/Significance: This approach serves as a first step to reclassify Crohn’s disease. The used technique can be
applied to other common complex diseases as well, and will help to complete patient characterization, in order to evolve
towards personalized medicine.
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Introduction
Crohn’s disease (CD) is a heterogeneous disorder with
differences in severity, location, behavior and age at onset of
inflammation. The heterogeneity of the disease has important
implications towards clinical management: patients with a more
severe disease course might benefit from early introduction of
immunomodulators and/or biologicals, while patients with
favorable disease prognosis could be spared from intense treatment
and possible side-effects.
The genetic background of CD has been extensively evaluated.
This has led to significant insights into the mechanism of the
disease, such as a disturbed surveillance of bacteria of the
microflora by the intestinal mucosa (NOD2), dysregulation of
adaptive immunity (IL23R), or deficient autophagy (ATG16L1,
IRGM). Meta-analysis of three CD GWAS have identified more
than 30 loci associated to CD, with odds ratios (OR) ranging from
1.08 to 3.99 [1]. As a general principle of complex traits, particular
disease associated variants are found with increased frequency in
patients when compared to controls. However, these variants
appear neither unique nor necessary for the disease to express
itself. Furthermore, attempts have been made to link the associated
genetic variants with the classic clinical CD subphenotypes. A
clear association has been found for NOD2/CARD15 variants and
ileal disease location [2–5]. However, for none of the other
susceptibility genes, a robust association with any of these clinical
subphenotypes could be shown. Our group recently examined
whether the associated genes or a combination thereof could
predict clinical outcome of CD. We showed that presence of risk
alleles at some of the CD-associated genetic loci influenced disease
progression, but overall the predictive power of these risk alleles
was fairly poor [6].
The genetic contribution to Crohn’s disease is without a doubt,
as is the fact that not all CD patients have the same disease course.
Although there are little robust genotype-phenotype associations
described for CD, we hypothesize that subgroups of CD patients
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do exist on a molecular level. Here we report on our efforts to
reclassify Crohn’s disease into subgroups based on currently
confirmed genetic markers. We then analyzed whether these




875 CD patients previously described in [6] were included in
this study. In brief, patients were recruited in the framework of the
inflammatory Bowel Disease (IBD) genetics study that started in
1997 at the IBD unit of the University Hospital in Leuven
(Belgium). Patients were unrelated and of Western European
origin. Diagnosis of CD was based on the most recent
international classification (Montreal classification) [7,8]. Median
time of follow-up since diagnosis is 14 years (IQR 7–22 years). The
control group consisted of 367 unrelated healthy volunteers
(healthy control HC) of Western European origin, without a family
history of IBD or other immune related disorders. Ethical
approval was given by the Ethics Board of the University Hospital
Leuven, and written informed consent was obtained from all
participants. Samples and data were stored in a coded,
anonymized database. Patient files were reviewed for phenotypic
information as described in [6] (also see Table 1, ‘Overall’).
DNA extraction and genotyping
DNA extraction and genotyping was performed as described
earlier [6]. A total of 46 markers identified from different GWAS
performed on CD, and/or meta-analysis of these GWAS [1], were
included in this study. Table S1 includes a list of all SNPs, with the
reference where the SNP was selected from, as well as the odds
ratio found in that study. In Table S2, allele and genotype counts
in the CD patients and HCs studied here are listed. The minor
allele was defined as the less frequent allele in the control group.
For the analysis performed in this study, coding for the additive
genetic model was used with wild-type individuals (homozygous
for the major allele) coded as 0, heterozygous individuals as 1, and
individuals homozygous for the minor allele as 2.
Statistical analyses
Detailed information on the used statistical analyses can be
found in the supporting information (Methods S1) online.
Cluster identification. To identify clusters, latent class
analysis (LCA) was applied to the set of 46 genetic markers
genotyped in CD patients and healthy controls. Analyses were
performed in the patient and control group separately. LCA
assumes that the population is composed of sub-populations (latent
classes), each having its distinctive distribution of the included
variables [9].
LCA was performed with Multimix, which can handle both
continuous and categorical variables [10], as well as missing data
[11]. Hence, for this study all individuals - including those with
missing genotypes - were included. Class assignment was based on
posterior probabilities. In particular, individuals were allocated to
classes or clusters on the basis of highest membership probability.
The number of latent classes (N) was derived from bootstrap p-
values for the likelihood ratio (LR) test with the null hypothesis
that the population is ‘best’ explained by N classes. The alpha level
used for determining the number of latent classes is 0.05. Per
model, 20 bootstrap samples were generated, making sure that the
same percentages of missingness as in the original sample were
attained.
Construction of classification trees. Once subjects were
grouped into classes or clusters, on the basis of their available
genetic information, we determined the genetic markers that
contributed most to the formation of the clusters. To perform this
step, i.e. to gain insight into the meaning of the formed clusters,
Table 1. Characteristics of all included CD patients (Overall), and of the six genetic-based subgroups (Cluster A–F).
Genetic-based subgroup Overall Cluster A Cluster B Cluster C Cluster D Cluster E Cluster F
Subjects n 875 302 96 62 117 59 239
Gender n(%)
Male 360 (41%) 120 (40%) 44 (46%) 30 (48%) 52 (44%) 25 (42%) 89 (37%)
Female 515 (59%) 182 (60%) 52 (54%) 32 (52%) 62 (56%) 34 (58%) 150 (63%)
Median age at diagnosis (Q25–Q75) 24 (18–31) 23 (18–31) 25 (18–32) 25 (19–32) 23 (17–30) 24 (20–32) 25 (18–33)
Location n(%)
Colon1 113 (13%) 34 (11%) 15 (16%) 3 (5%) 17 (15%) 9 (15%) 35 (15%)
Ileum1 326 (37%) 107 (35%) 36 (38%) 32 (52%) 46 (39%) 19 (32%) 86 (36%)
Ileocolonic1 433 (50%) 161 (53%) 44 (46%) 27 (44%) 54 (46%) 31 (53%) 116 (49%)
Anal 331 (38%) 118 (39%) 33 (34%) 26 (42%) 51 (44%) 15 (25%) 88 (37%)
Behavior n(%)
Inflammatory* 430 (49%) 144 (48%) 57 (59%) 23 (37%) 60 (51%) 30 (51%) 116 (49%)
Stenosing* 329 (38%) 115 (38%) 33 (34%) 31 (50%) 36 (31%) 18 (31%) 96 (40%)
Non-perianal fistulae 227 (26%) 82 (27%) 16 (17%) 18 (29%) 33 (28%) 16 (27%) 62 (26%)
Perianal fistulae* 267 (31%) 73 (29%) 31 (32%) 26 (42%) 34 (29%) 17 (29%) 73 (31%)
Surgery# n(%) 493 (57%) 171 (57%) 54 (56%) 45 (73%) 62 (53%) 31 (53%) 130 (54%)
1three missing values. Colonic, ileal, and ileocolonic location add up to 100% (are mutually exclusive). Anal disease can occur together with any of the other locations,
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classification trees were generated with the R rpart package (R
2.9.1). Hence, trees were grown using the cluster variable obtained
from Multimix as the (categorical) response and SNPs as potential
explanatory variates. Goodness-of-fit of the obtained classification
tree was compared to the cluster assignment of Multimix, by
dropping individuals down the classification tree, and by
comparing the R tree-based classification of subjects to the
Multimix-based one.
Testing of the hypothesis of no overall status effect (case
vs. control). To check for the effect of status (case vs. control),
canonical discriminant analysis (CDA) was applied to LCA data of
both CD patients and healthy controls (SAS 9.1.3). Two analyses
were performed: (analysis 1) To globally look at the differences
between CD patients and healthy controls, canonical variables
were calculated for CD patients only (say Y1, Y2), and for healthy
controls only (say X1, X2). In CDA, Y1,Y2 and X1,X2 are chosen
so as to maximize separation between the clusters. (analysis 2) To
test whether there is a difference in terms of clustering spread/
separation rule between CD patients and healthy controls,
canonical variables were computed for CD patients only (say
Y1, Y2). The values of Y1 and Y2 were subsequently computed for
the healthy controls using the ‘‘linear combination’’ rule derived
for the CD patients. Mean values of Y1 and Y2 between CD
patients and healthy controls were then compared using
MANOVA.
Association of genetic-based subgroups and clinical
characteristics. Univariate Chi-squares (or Fisher Exact tests
when necessary) were performed using SPSS 15.0 to test for
associations between each of the cluster memberships and the
clinical subphenotypes gender; colonic, ileal, ileocolonic disease
location at last follow-up; anal disease at last follow-up;
inflammatory, stricturing, non-perianal fistulizing, or perianal
fistulizing disease behavior at last follow-up; and need for surgery.
Multiple logistic regression (using automated backward variable
selection) was performed including those clinical parameters that
showed at least a trend towards significance in univariate analysis
(cut-off p-value = 0.1) using SPSS 15.0. These tests were
complemented with Random Forest (RF) analysis in R (2.9.1;
http://www.stat.berkeley.edu/,breiman/RandomForests/cc_home.
htm). RF analysis estimates the importance of variables in
determining classification and is able to highlight possible variable
interactions.
Results
Cluster identification in CD patients
Latent class analysis (LCA) identified 6 genetic-based subgroups
(clusters) in CD. For each patient, membership probabilities for
each cluster were computed. As mentioned above, an individual
was assigned to the cluster for which they had the highest
probability. 90% of CD patients (n = 788) had a highest
membership probability of .0.9, indicating clear membership.
For 4% of CD patients (n = 37) the highest membership
probability was ,0.6, indicative of more uncertain membership
(see Table S3 for all membership probabilities).
To investigate the relationship between subgroups identified in
the different steps of the model building, the number of CD
patients ‘‘flowing’’ from a cluster identified in one step (‘Model i’
(i$1), e.g. a model with one cluster) to a cluster identified in the
next step (‘Model i+1’, e.g. a model with two clusters) was
determined (Figure 1A). Notably, the majority of patients who
belong to a particular cluster in ‘Model i’, tend to be redistributed
to a single cluster in ‘Model i+1’, as can be observed by inspecting
connected clusters in Figure 1A: the white parallelograms
connecting two clusters, one from ‘Model i’ and one from ‘Model
i+1’, the area of which is proportional to the number of individuals
that are common to the clusters.
The grouping into the 6 CD clusters was best explained by 3
SNPs (rpart analysis; Figure 1B): rs7869487 in TNFSF15,
rs13361189 in IRGM, and rs946227 located on 6q23.3.
When dropping the CD patients down the SNP tree, only 39
CD patients (4.5%) were misclassified compared to the multimix
cluster allocation. A total of 58 CD patients (6.6%) could not be
allocated to any of the CD subgroups because of missing genotypes
for at least one of the determining SNPs.
Cluster identification in control samples
If patient genotypes would cluster purely at random, then the
same clusters are to be expected in the control samples. We
therefore ran the Multimix program (LCA) also on 367 healthy
controls (HC). A model with 5 clusters best explained the
heterogeneity in healthy controls. A total of 83% of HC
(n= 305) had a highest membership probability of .0.9,
indicating clear membership. For 4.6% of HC (n= 17) the highest
membership probability was ,0.6, which is indicative of highly
uncertain cluster membership assignments (data not shown).
The ‘‘flow’’ of control individuals through the clusters and
formation of the clusters in the stepwise models is shown in
Figure 1C. As we observed for the CD patients LCA analysis,
identified clusters appeared to be stable across the different
models.
Tree building with rpart showed that the following SNP
combinations best explained the control clusters (Figure 1D):
rs7869487 in TNFSF15, rs6927210 on chromosome 6, rs10883365
and rs7081330 in NKX2-3, and rs4958847 in IRGM. Cluster B
could not be explained by specific SNPs, and may be interpreted
as a waste bin: with the available genetic markers, no SNP
appeared to be more important than others to explain cluster B.
We observed that 79 healthy controls (21.5%) were misclassi-
fied. Moreover, 39 HC (10.6%) were not allocated to a control
cluster because of missing genotypes in at least one of the best
determining SNPs, when dropped down the control SNP tree.
This high prediction error rate is partly explained by the lack of
any SNP-based rule for cluster B.
Comparing formed clusters between CD patients and
healthy controls
Canonical discriminant analysis (CDA) was performed in CD
patients and healthy controls, separately. The means derived for
canonical variable 1 (X1, Y1) and canonical variable 2 (X2,Y2),
with (X1, X2) for healthy controls and (Y1, Y2) for CD patients,
were: mean value X1: 7.93E-17, SD 2.06; mean value Y1: 7.72E-
17, SD 2.61; mean value X2: 22.68E-16, SD 2.36; mean value
Y2: 1.96E-16, SD 1.55. When we constructed a plot based on the
two main canonical variables for CD patients (Y1, Y2; Figure 2A)
and on the two main canonical variables for healthy controls
(X1,X2; Figure 2B), a clear difference between both groups in
terms of spatial spread of the clusters could be observed (compare
Figures 2A and 2B). This supports the existence of differential
separation rules for CD patients and healthy controls. Indeed,
when canonical variables for healthy controls were computed
using the discriminant rule derived for CD patients (analysis 2; see
Methods for details), the obtained mean values for the two first
canonical variables for CD patients and healthy controls were
significantly different (pmanova,0.0001). Whereas the first two
canonical variables nicely separated the CD clusters, the
corresponding discriminant function did not clearly separate the
clusters in healthy controls (compare Figures 2A and 2C).
Molecular Classification of CD
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Note that one cluster (cluster D in Figure 2A), was less confined
to a particular spatial area than the other clusters derived for CD
patients. This was to be expected since this cluster was determined
by two different branches from the tree plot (see Figure 1B).
Healthy controls were also nicely separated on the basis of the two
first canonical variables for HC, although to a lesser extent than
the CD clusters. This was also reflected in the higher prediction
error rate in HC compared to CD patients. Here, cluster B seemed
to smear out over the plotted area, which was in agreement with
the SNP tree (see Figure 1D), where cluster B does not appear. As
stated above, for this cluster, no preference was given to any SNP
to determine the cluster.
Comparing clinical subphenotypes across the identified
clusters
The phenotypic characteristics of CD patients in the different
genetic-based subgroups are summarized in Table 1. No obvious
differences were observed for gender distribution and median age
at diagnosis between the different clusters. However, a difference
in distribution of disease location (colonic, ileal, or ileocolonic)
Figure 1. Modelbuilding process and classification trees for the final model. Formation of genetic-based subgroups when the number of
clusters was increased stepwise for CD patients (panel A) or healthy controls (panel C) is shown. Data are presented as n (%). Box widths are
proportional to the number of individuals in the respective cluster. The area of the white parallelograms connecting two clusters, one from Model i
and one from Model i+1, is proportional to the number of individuals that are common between these clusters. Tree plot showing how SNPs
determine the grouping of individuals into the different clusters for CD patients (panel B) and healthy controls (panel D). The diamond indicates
where a decision is made (genotype 0 (wild-type), 1 (heterozygous) and/or 2 (homozygous mutant)). A rectangle indicates the decision (which cluster
the patient belongs to when following the tree). The number and percentage of individuals in each cluster is presented as well.
doi:10.1371/journal.pone.0012952.g001
Molecular Classification of CD
PLoS ONE | www.plosone.org 4 September 2010 | Volume 5 | Issue 9 | e12952
could be observed between cluster C, and the other clusters
(pChi2 = 0.02). Prevalence of anal disease, which could occur
irrespective of the other disease locations, was lowest in cluster E
(15/59 CD patients, 25%), followed by cluster B (33/96, 34%),
cluster F (88/239, 37%), cluster A (118/302, 39%), cluster C (26/
62, 42%), and cluster D (51/117, 44%). With regards to disease
behavior, the prevalence of inflammatory disease behavior was
highest in cluster B (57/96 CD patients, 59%), less in cluster E
(30/59, 51%) and D (60/117, 51%), followed by cluster F (116/
239, 49%) and A (144/302, 48%), and lowest in cluster C (23/62,
37%). This difference (cluster B versus all other clusters) was,
although borderline, statistically significant (pChi2 = 0.04,
OR=1.59[1.03–2.44]). In addition, cluster B contained the lowest
prevalence of non-perianal fistulae (16/96, 17%), compared to
26%–29% in the other clusters (pChi2 = 0.03, OR=0.54[0.31–
0.94]). Stenosing disease behavior, and perianal fistulizing disease
behavior, tended to be more prevalent in cluster C: 31/62 (50%)
CD patients in cluster C had stenosing disease behavior versus
31%–40% in the other clusters (pChi2 = 0.04, OR=1.73 [1.03–
2.90]), and 26/62 (42%) CD patients had perianal fistulizing
disease behavior versus 29%–31% in other clusters (pChi2 = 0.04,
OR=1.71 [1.01–2.90]). Also interesting was the high prevalence
of surgery in cluster C: 45 out of 62 CD patients (73%) underwent
surgery for their disease, compared to 53%–57% of CD patients in
the other clusters. This difference (cluster C versus other clusters)
was statistically significant (pChi2 = 0.008, OR=2.13[1.2–3.79]).
Multiple logistic regression analysis including all clinical param-
eters with p,0.1, indicated that cluster B remained independently
associated with non-perianal fistulizing disease behavior (p = 0.03,
OR=0.54 [0.31–0.95]; cluster C with perianal fistulizing disease
behavior (p = 0.03, OR=1.82 [1.07–3.14] and need for surgery
(p = 0.03, OR=1.92 [1.07–3.45]; and cluster E with anal disease
(p = 0.04, OR=0.54 [0.29–0.98]. It should be noted however, that
all differences seen between the different clusters are modest in
magnitude, and would not withstand correction for multiple
testing.
On the other hand, random forest (RF) analysis applied to our
data gave rise to large inconsistencies between the permutation-
based mean decrease in accuracy criterion and the mean decrease
Gini impurity criterion, indicating which variable would be the
most and least important. From the observation that RF also
showed a considerable classification error rate (71,31%) it could be
presumed that the given clinical subphenotypes are inadequate or
not sufficient to serve as sole class predictors.
Discussion
Crohn’s disease (CD) is a heterogeneous disorder which is
classically being classified according to extent and location of
disease and its behavior (inflammatory, stenosing or fistulizing)
[7,8]. Except for the association between NOD2 and ileal disease
location, no robust genotype-phenotype associations have been
reported for CD. Because of the well-established role for genetics
in the etiology of Crohn’s disease, we looked whether subgroups of
CD patients could also be identified based only on genetic marker
information, and treating the clinical subphenotypes as unknown.
The applied technique distinguished six genetic-based sub-
groups in CD patients. Several genetic-based subgroups were also
identified in healthy controls, but these clearly had a different
pattern than in CD patients (Figure 2, panels A and B). The
discriminant function for separation of clusters in CD patients
indeed could not clearly separate the clusters in healthy controls
(Figure 2, panel C; and CDA analysis 2). The genetic variants thus
clustered in different ways within CD patients and healthy
controls. Note that these clusters were derived directly from
genetic marker data, completely independent from any a priori
knowledge about clinical (sub)phenotypes.
Many of the genes/loci found to be associated with Crohn’s
disease segregate into particular pathways. Two of the key
pathways are the autophagy and the Il23/Th17 pathway [12–
15]. Among the most widely studied and replicated disease loci
associated with CD are indeed the autophagy genes ATG16L1
(rs2241880) [14] and IRGM (rs4958847, rs13361189) [15], NOD2
(rs2066844, rs2066845, and rs2066847) [16,17], and IL23R
Figure 2. Cluster plots. Cluster plot based on canonical variables for
CD patients (panel A) and for healthy controls (panel B). Cluster plot
for healthy controls, when discriminant functions derived from CD
patients were applied to the healthy control population (panel C).
doi:10.1371/journal.pone.0012952.g002
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(rs11209026) [18]. Although these markers were included in this
study, except for IRGM, they did not clearly pop up in the SNP
classification tree as best predicting the identified clusters. In this
study, we are actually searching for (a combination of) genetic
factors that distinguish CD patients from one another, as opposed
to factors that are common to all CD patients (versus healthy
controls). These particular SNPs are strong susceptibility markers
for CD when compared to healthy controls, and could thus be
more generally applicable to all CD patients, which could explain
why they do not appear in the classification trees. It is indeed
believed that genetics of Crohn’s disease consists of disease
susceptibility genes/loci on the one side, and disease modifying
genes/loci on the other. Recent work from the international IBD
genetics consortium underscores this idea: re-analysis of GWAS
data in function of disease behavior (mild versus aggressive disease)
identified a number of SNPs that specifically predispose to a more
aggressive disease course in CD. Interestingly, these SNPs were
not associated with the disease in the original GWAS (Lee et al.,
ECCO 2010). Additionally, an important observation in our study
was that the SNPs/genes that determine cluster formation in CD
do not appear to group in specific pathways: eg TNFSF15 and
IRGM, which explain cluster B (Figure 1B) are – to the best of our
knowledge – not part of one and the same pathway. It could thus
be postulated that there are (more general) disease susceptibility
pathways that lead to CD overall as compared to healthy controls:
autophagy, Th17 pathway, innate immunity, … . But that the
specific disease subphenotype (whether a patient will develop a
severe disease phenotype with need for surgery for example) is
dependent on single disease modifying genes that are not
necessarily playing on different levels of the same pathway.
Weersma et al. showed that an increase in the number of risk
alleles is associated with an increased risk for Crohn’s disease and
with a more severe disease course [19]. Still, the absolute
difference in the number of risk alleles between patients with
Crohn’s disease and controls was modest. Also, even in the
extensive CD group studied by Weersma et al., the majority of
patients carried up until 6 risk alleles, and only 5 CD patients
carried 8 risk alleles [19]. It is expected that a plateau phase is
reached with respect to the number of risk alleles patients carry. It
could therefore be speculated that individuals carrying a specific
set of risk alleles clustering in specific pathways (for example in
IRGM, ATG16L1 and NOD2 – all implicated in autophagy), and
maybe having been/being exposed to a same environmental
factor(s), end up developing CD. When in these patients, a
combination of genotypes at different risk loci – all of which part of
different pathways – is present (cfr as in the SNP classification
tree), the patient will end up developing a specific disease
subphenotype, independent from the development of CD overall.
Among the clusters, modest differences in prevalence of disease
location and/or behavior could be observed (Table 1). For
example, cluster B contained less patients with non-perianal
fistulizing disease behavior at last follow-up, and cluster C had a
higher prevalence of patients with perianal fistulae and patients
with need for surgery. Still, random forest analysis, which
estimates the importance of variables in determining classification,
showed that CD subgroups found based on genetic data could not
be explained adequately by the known clinical (sub)phenotypes.
This points to a poor relationship between the genetic-based
subgroups and the used clinical subphenotypes. Different expla-
nations could be put forward: (1) A relatively low number of SNPs
was included in this exploratory study. It will be important to – in
the future – include many more variants in this type of analysis, to
look for subgroups within patients. At that time, it will also be
important to re-assess the above-mentioned concept of disease
susceptibility pathways leading to disease overall, and single disease
modifying genes defining the specific disease course. (2) As also mentioned
above, the genetic variants included in this study are known
susceptibility SNPs for CD versus healthy controls. The observation
that the strongest associated loci to date (CARD15, ATG16L1,
IL23R) did not pop up in the classification tree supports the
hypothesis that they are indeed more general genes for CD, and
might be less usefull to differentiate CD patients. More studies are
needed to also discover markers for clinical subphenotypes. (3) CD
has a heritability estimate of 50–60% (with ls,20–35). The
proportion of heritability accounted for by the currently known
susceptibility loci is about 20% [1]. The currently known variants
might explain too little of the genetic part of disease risk to be of
much clinical relevance. It is believed that part of the missing
heritability is explained by gene-gene interactions, that might be
even more important than the independent effects of the single
susceptibility genes. A clustering analysis like performed in this
study gives a first indication of potentially interacting markers: cfr
on one branch of the tree (Figure 1B), one SNP is a potential effect
modifier of another SNP on the same branch. Another aspect of
the missing heritability are copy number variations, which in the
future should be taken up as parameters in this type of analysis. (4)
Although speculative, another reason might be that the currently
used clinical parameters are not the best way to subclassify CD
patients, or at least not in the genetic context. The classification
based on extent and location of disease indeed is of limited
practical use for clinical application, and for prediction of disease
progression. Attempts have been made to better subclassify CD
patients using clinical, as well as serological and genetic markers,
but diagnostic and prognostic specificity and sensitivity of these
methods are generally too low to be useful in clinical practice
[7,20,21]. Still, from the clinical point of view, the clinical
characteristics will continue to be most relevant.
With this study we could identify CD specific genetic-based
subgroups, pointing to a non-random clustering of genetic markers
in CD patients. The formed CD clusters are likely to contribute to
disease pathogenesis. The specific SNP combinations determining
the CD clusters could be promising disease (progression)
predictors, and deserve future study once internationally ongoing
efforts to develop a disability score will be finished. In order to
further improve the classification based on genetic markers, in the
future, more markers need to be included, even on a genome-wide
level. Since this is an exploratory study, validation in independent
data sets is necessary. Nevertheless, this technique may serve as a
first step to reclassify Crohn’s disease. Similar approaches could be
interesting also for other complex diseases, and in for example
pharmacogenetics where the goal is to find subgroups of patients
benefiting most, or being most at risk for side-effects of certain
therapies.
Supporting Information
Methods S1 Supporting methods
Found at: doi:10.1371/journal.pone.0012952.s001 (0.06 MB
DOC)
Table S1 Summary of included polymorphisms: reference and
odds ratio as given in the discovery study.
Found at: doi:10.1371/journal.pone.0012952.s002 (0.03 MB
XLS)
Table S2 Allele and genotype counts in Crohn’s disease (CD)
patients and healthy controls.
Found at: doi:10.1371/journal.pone.0012952.s003 (0.04 MB
XLS)
Molecular Classification of CD
PLoS ONE | www.plosone.org 6 September 2010 | Volume 5 | Issue 9 | e12952
Table S3 Membership probabilities for Crohn’s disease patients.
Found at: doi:10.1371/journal.pone.0012952.s004 (0.13 MB
XLS)
Acknowledgments
The authors thank Ben Spycher for all professional advice with regards to
the applied LCA clustering technique (Multimix), Vera Ballet for excellent
database management, and Karolien Claes, Tamara Coopmans, Sophie
Organe, and Nele Van Schuerbeek for the excellent technical and scientific
support for sample selection, DNA extraction, and genotyping.
Author Contributions
Conceived and designed the experiments: IC PR KVS SV. Performed the
experiments: IC JMMJ. Analyzed the data: IC. Contributed reagents/
materials/analysis tools: LH WVM. Wrote the paper: IC JMMJ LHWVM
PR KVS SV.
References
1. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, et al. (2008) Genome-
wide association defines more than 30 distinct susceptibility loci for Crohn’s
disease. Nat Genet 40: 955–962.
2. Vermeire S, Wild G, Kocher K, Cousineau J, Dufresne L, et al. (2002) CARD15
genetic variation in a Quebec population: prevalence, genotype-phenotype
relationship, and haplotype structure. Am J Hum Genet 71: 74–83.
3. Hampe J, Grebe J, Nikolaus S, Solberg C, Croucher PJ, et al. (2002) Association
of NOD2 (CARD 15) genotype with clinical course of Crohn’s disease: a cohort
study. Lancet 359: 1661–1665.
4. Cuthbert AP, Fisher SA, Mirza MM, King K, Hampe J, et al. (2002) The
contribution of NOD2 gene mutations to the risk and site of disease in
inflammatory bowel disease. Gastroenterology 122: 867–874.
5. Ahmad T, Armuzzi A, Bunce M, Mulcahy-Hawes K, Marshall SE, et al. (2002)
The molecular classification of the clinical manifestations of Crohn’s disease.
Gastroenterology 122: 854–866.
6. Henckaerts L, Van Steen K, Verstreken I, Cleynen I, Franke A, et al. (2009)
Genetic Risk Profiling And Prediction Of Disease Course In Crohn’S Disease
Patients. Clin Gastroenterol Hepatol.
7. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, et al. (2005)
Toward an integrated clinical, molecular and serological classification of
inflammatory bowel disease: Report of a Working Party of the 2005 Montreal
World Congress of Gastroenterology. Can J Gastroenterol 19 Suppl A: 5–36.
8. Satsangi J, Silverberg MS, Vermeire S, Colombel JF (2006) The Montreal
classification of inflammatory bowel disease: controversies, consensus, and
implications. Gut 55: 749–753.
9. McLachlan G, Peel D (2000) Finite Mixture Models; Series W, editor. New
York: John Wiley & Sons. 456 p.
10. Hunt L, Jorgensen M (1999) Mixture Model clustering using the MULTIMIX
program. Aust N Z J Stat 41: 154–171.
11. Hunt L, Jorgensen M (2003) Mixture model clustering for mixed data with
missing information. Computational Statistics & Data Analysis 41: 429–440.
12. Wang K, Zhang H, Kugathasan S, Annese V, Bradfield JP, et al. (2009) Diverse
genome-wide association studies associate the IL12/IL23 pathway with Crohn
Disease. Am J Hum Genet 84: 399–405.
13. McGovern DP, Rotter JI, Mei L, Haritunians T, Landers C, et al. (2009)
Genetic epistasis of IL23/IL17 pathway genes in Crohn’s disease. Inflamm
Bowel Dis 15: 883–889.
14. Rioux JD, Xavier RJ, Taylor KD, Silverberg MS, Goyette P, et al. (2007)
Genome-wide association study identifies new susceptibility loci for Crohn
disease and implicates autophagy in disease pathogenesis. Nat Genet 39:
596–604.
15. Parkes M, Barrett JC, Prescott NJ, Tremelling M, Anderson CA, et al. (2007)
Sequence variants in the autophagy gene IRGM and multiple other replicating
loci contribute to Crohn’s disease susceptibility. Nat Genet 39: 830–832.
16. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, et al. (2001)
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s
disease. Nature 411: 599–603.
17. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, et al. (2001) A
frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease.
Nature 411: 603–606.
18. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, et al. (2006) A
genome-wide association study identifies IL23R as an inflammatory bowel
disease gene. Science 314: 1461–1463.
19. Weersma RK, Stokkers PC, van Bodegraven AA, van Hogezand RA,
Verspaget HW, et al. (2009) Molecular prediction of disease risk and severity
in a large Dutch Crohn’s disease cohort. Gut 58: 388–395.
20. Vasiliauskas EA, Kam LY, Karp LC, Gaiennie J, Yang H, et al. (2000) Marker
antibody expression stratifies Crohn’s disease into immunologically homoge-
neous subgroups with distinct clinical characteristics. Gut 47: 487–496.
21. Mow WS, Vasiliauskas EA, Lin YC, Fleshner PR, Papadakis KA, et al. (2004)
Association of antibody responses to microbial antigens and complications of
small bowel Crohn’s disease. Gastroenterology 126: 414–424.
Molecular Classification of CD
PLoS ONE | www.plosone.org 7 September 2010 | Volume 5 | Issue 9 | e12952
